Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter study of health-related quality of life using emicizumab among Thai hemophilia patients with and without inhibitor
TCTR20220328004Not yet recruiting
- Sponsor
- N/A
- Start
- Apr 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of emicizumab in hemophilia A, sponsored by N/A. Primary endpoint: Health-related quality of life. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on TCTR20220328004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220328004.